Burkitt's lymphomas (BLs) are characterized by an activated MYC gene that provides a constitutive proliferative signal. However, activated myc can initiate ARF-dependent activation of p53 and apoptosis as well. Data derived from cell culture and animal models suggest that the inactivation of the ARF-MDM-2-p53 apoptotic signaling pathway may be a necessary secondary event for the development of BL. This has not been tested in freshly excised BL tissue. We investigated the ARF-MDM-2-p53 pathway in tumor specimen from 24 children with sporadic BL/B-ALL. Direct sequencing revealed a point mutation in the p53 gene in four BL. Overexpression of MDM-2 was evident in 10 of the BL samples analyzed by real-time quantitative PCR. Deletion of the CDKN2A locus that encodes ARF or reduced expression of ARF could not be detected in any BL by fluorescence in situ hybridization analysis or real-time quantitative PCR, respectively. Our results indicate that the ARF-MDM-2-p53 apoptotic pathway is disrupted in about 55% of the cases of childhood sporadic BL. We suggest that in addition to the inactivation of the ARF-MDM-2-p53 protective checkpoint function other antiapoptotic mutations may occur in a substantial part of children with sporadic BL.
Introduction
Burkitt's lymphoma (BL) comprises a group of aggressive B-cell non-Hodgkin's lymphomas. Almost exclusively confined to children, adolescents and young adults it occurs as endemic form in association with EBV in Africa, as sporadic BL in Europe and North America and in association with an HIV infection in adults. The molecular hallmark of BL is the activation of the MYC oncogene on chromosome 8q24 by reciprocal translocation to the immunoglobulin heavy-chain locus on chromosome 14q32 (80%) or the kappa or lambda light-chain locus on chromosome 2p13 (15%) or 22q11 (5%), respectively. [1] [2] [3] [4] MYC activation leads to cell cycle progression, inhibition of differentiation and a general stimulatory effect on cellular metabolism, thereby promoting cell proliferation and even genomic instability. [1] [2] [3] [4] In contrast, apart from promoting cell division, the activation of MYC can initiate an endogenous apoptotic program and sensitizes cells to diverse apoptotic stimuli. [5] [6] [7] An important mediator of myc-induced apoptosis in mouse embryo fibroblasts is the ARF-MDM-2-p53 tumor suppressor pathway. [7] [8] [9] MYC activates the tumor suppressor ARF, a protein encoded by an alternative reading frame of the CDKN2A locus. 9, 10 ARF binds and inhibits the p53 antagonist MDM-2 that targets p53 for proteasome-mediated degradation through nuclear export. [11] [12] [13] [14] [15] [16] ARF sequesters MDM-2 in the nucleoli and inhibits the ubiquitin ligase activity of MDM-2, leading to the accumulation of p53. 17, 18 Disruption of the ARF-MDM-2-p53 pathway has been found in the majority of B-cell lymphoma of mice expressing the MYC gene under the control of the immunoglobulin heavy-chain enhancer. 19, 20 Deletion of this safeguard mechanism greatly accelerates lymphomagenesis and only p53-null bone marrow cells infected with an MYC encoding retrovirus are tumorigenic. [19] [20] [21] Recently, the ARF-MDM-2-p53 apoptotic pathway has been found to be altered in all 18 BL cell lines tested for deletion of ARF, overexpression of MDM-2 or mutations in the p53 gene. 22 Based on these data from murine models and cell lines, the inactivation of the p53 pathway is considered to be the conditio sine qua non second hit for the progression of MYC overexpressing hyperproliferative cells towards a clinical manifest BL.
However, there are limited data from studies of freshly excised BL tissue to support this view. P53 mutations have been found in 20-40% of BL/B-ALL. [23] [24] [25] [26] [27] The INK4A/ARF locus was inactivated by deletion in one of 29 BL samples in a series of high-grade non-Hodgkin's lymphomas. 22, [28] [29] [30] An examination of MDM-2 overexpression has not been reported in tumor samples from BL. We therefore asked whether the ARF-MDM-2-p53 pathway is inactivated in tumor samples from a series of children with sporadic BL/B-ALL treated in the German NHL-BFM 95 study.
Patients and methods

Case selection and tissue samples
Bone marrow, ascites, pleura exsudate or lymph node samples from 24 patients with BL/B-ALL were collected after informed consent during standard diagnostic procedures. Histopathology was confirmed by central review in all cases. Cases were selected from all children with BL treated in the German NHL-BFM 95 study taking into account the existence of an adequate histopathological, immunophenotypic and molecular characterization, complete clinical data and the availability of representative snap-frozen tumor tissue for RNA and DNA extraction. The specimen contained at least 80% tumor cells in all cases. From 20 patients, unstained bone marrow or tumor smears were available for fluorescence in situ hybridization (FISH) analysis. Lymphocytes from 11 healthy blood donors were isolated and evaluated for MDM-2 and ARF expression by real-time PCR as well.
RNA isolation
Total RNA was purified with the help of a single-step protocol. The RNA was denatured at 701C for 5 min and, subsequently, the cDNA synthesis was carried out at 421C for 50 min in a total volume of 50 ml using random hexamer primers (Invitrogen, Groningen, The Netherlands).
Sequence analysis of p53
The entire p53 cDNA (accession number K03199) was amplified in two overlapping fragments. For the amplification of the first p53 fragment, we used 5 0 -CTTCCGGGTCACTGC-CATGGAGGA-3 0 and 5 0 -GCCAGACCATCGCTATCTGAG-3 0 oligoncleotides. The second p53 fragment was amplified with primers 5 0 -GTGAGGCGCTGCCCCCACCATGAG-3 0 and 5 0 -CTGAGTCAGGCCCTTCTGTCTTG-3 0 . PCR products were cloned by means of a TA cloning kit (Invitrogen, Groningen, The Netherlands) and five individual clones were sequenced for each fragment. To exclude any point mutations caused by misincorporation of nucleotides by Taq polymerase, all fragments were amplified, cloned and sequenced twice.
MDM-2 and ARF expression level
The quantitative real-time PCR was performed using the TaqMan assay in the ABI PRISMt 7700 Sequence Detector System (ABI/PE, Foster City, CA, USA). Primers and probes for the amplification of cDNA derived from MDM-2 and ABL/ PBGD/HPRT transcripts were designed using the Primer Express software program (ABI/PE, Foster City, CA, USA). The TaqMan probes labelled with a 5 0 FAM reporter dye molecule and a 3 0 TAMRA quencher group were synthesized by Eurogentec (Seraing, Belgium). In order to exclude the amplification of genomic DNA and to ensure that the PCR signal was generated from cDNA, primers were placed at exon-exon boundaries. In real-time PCR, the expression of a gene of interest is commonly related to that of a housekeeping gene to compensate for different RNA qualities.
We evaluated the expression of four possible housekeeping genes, measured by real-time PCR, in relation to total singlestranded cDNA, measured directly before real-time PCR using a method that is based on the nucleic acid stain OliGreen (Molecular Probes) (Rawer et al, manuscript in preparation). Among the various housekeepers v-abl Abelson murine leukemia viral oncogne homolog 1 (ABL), porphobilinogen deaminase (PBGD), hypoxanthine phosphoribosyltransferase (HPRT) and beta-2-microglobulin (B2M), ABL showed both the lowest overall variation and no difference between control samples and BL patients. Thus, it was finally chosen as housekeeping gene to normalize for the MDM-2 and ARF mRNA expression. The following oligonucleotides were used as primers and probes:
For the absolute quantification of gene expression in the samples, plasmid standards were generated. cDNA fragments of MDM-2 and ABL genes were amplified and cloned by means of a TA cloning kit (Invitrogen, Groningen, The Netherlands). To calculate the relative amount of ARF and ABL transcripts, the comparative Ct method for the relative quantitation was applied using the arithmetic formula 2 ÀWWCt (WWCt ¼ WCt P ÀWCt K ); P ¼ probe; K ¼ reference sample.
CDKN2A locus analysis
To detect deletions of the CDKN2A locus FISH was carried out on bone marrow blasts or tumor touch samples using the commercial LSI p16 (9p21)/CEP 9 Dual Color Probe (Vysis, Downers Grove, IL, USA). Hybridization and washing steps were performed according to standard procedures. For each investigated case, at least 100 interphase nuclei were evaluated. Controls included normal lymphocytes and a tumor with known loss of the CDKN2A locus.
Results and discussion
Clinical and pathological data of the patients are listed in Table 1 . First, the p53 gene status was analyzed by sequencing. Point mutations in the p53 gene were detected in four of the 24 specimen (16.7%) ( Table 2 ). This number lies at the lower border of the range of published series of BL biopsies (20-40%), which is lower than in BL cell lines (60-70%). [23] [24] [25] [26] [27] [31] [32] [33] [34] As in other studies, p53 mutations in our patients with BL cluster in exon 7 (Table 2 , codon 245 and 246), which codes for the DNAbinding domain of p53. 24, 34 The mutation of codon 92 has only been described in three tumors so far. 35 It changes one amino acid in the proline-rich region and its functional consequences are unclear.
Overexpressed MDM-2 can inactivate p53 by binding to the transactivation domain of p53 and by export of p53 from the nucleus to the cytoplasm and degradation. The overexpression of MDM-2 has been described in four of five and four of seven BL cell lines that carry wild-type p53.
22,36 Next, we therefore examined the expression of MDM-2-mRNA in all BL specimen by quantitative TaqMan-RT-PCR. The expression levels were compared to the expression in blood samples of 11 healthy blood donors. Five BL samples showed a marked and another five a more slight but still remarkable overexpression of MDM-2 compared to the other BL samples and the samples from blood donors (Figure 1) . One of the five tumors with marked overexpression also had the p53 mutation in codon 92 with unproven functional consequences. Thus, nine of 20 or 10 of 21 (45-48%) BL with wild-type p53 showed an inactivation of the p53 pathway through increased expression of MDM-2-mRNA ( Table 2) . As for p53, the percentage of MDM-2-overexpressing tumors seems to be lower in primary biopsy specimen of BL than in cell lines, although the numbers are small 22, 36 (Table 2 ). The paradigm from the cell culture studies that no tumor carries both a mutation of p53 and an overexpression of MDM-2 holds true in freshly excised tumors provided that the p53 mutation in codon 92 in the proline-rich region may not inactivate p53 function. 22, 36 The upstream regulation of MDM-2 is through the ARF protein. ARF stabilizes p53 by inhibiting MDM-2.
11-16 ARF can theoretically be inactivated by homozygous deletion of the CDKN2A locus, via deletion of exon 1b, methylation of the ARF promotor or overexpression of the Bmi-1 or Twist transcription ARF-Mdm-2-p53 inactivation in Burkitt's lymphoma M Wilda et al factors that repress the ARF promotor. 37 However, the latter three mechanisms could neither be detected in cell lines nor in biopsy specimen of BL so far. 22, 28 Deletion of the CDKN2A locus was evident in three of seven BL cell lines with wild-type p53 (altogether three of 18), but in only one of 26 BL biopsies. 22, 30 We analyzed the possible inactivation of ARF by a search for deletion of the CDKN2A locus by FISH and expression of ARF -mRNA. None of the 19 BL specimen showed a deletion of the locus (Figure 2 ) and decreased expression of ARF could not be detected in any tumor (Figure 3) . Altogether, ARF-Mdm-2-p53 inactivation in Burkitt's lymphoma M Wilda et al the inactivation of ARF does not play a major role in the disruption of the p53 apoptotic signaling pathway in BL. In all, 10 of 23 tumors overexpressed ARF (Figure 3 ), seven of which had either a mutation in the p53 gene or overexpressed MDM-2, consistent with a disruption of the p53-ARF feedback loop. The high level of ARF expression in three additional tumors implies that the p53 pathway might be inactivated by mechanisms downstream of ARF other than p53 mutation or MDM-2 overexpression.
Our series is small and childhood BL have an excellent prognosis when treated according to current chemotherapy protocols (EFS 85-90%), 38 so that we cannot correlate the inactivation of the ARF-p53 pathway with the outcome. From the three deaths attributable to tumor progression, two occurred in patients with a disruption of the p53 pathway and the last in a patient with no detectable disruption who did not overexpress ARF either. In one series of 48 patients with BL, no correlation of p53 mutations with extensive tumor mass, poor response to an intensive chemotherapy regimen or outcome could be detected. 26 However, MDM-2 overexpression was not analyzed in that study.
In conclusion, our data demonstrate that the ARF-MDM-2-p53 apoptotic pathway is inactivated in about 55% of primary sporadic BL by either a mutation in p53 or overexpression of MDM-2. The overexpression of MDM-2 was detected twice as often as the cause of disruption of the p53 pathway than a mutation in p53. In the remaining cases of BL, either mechanisms other than those tested in our study may inactivate the p53 pathway or disruption of apoptotic pathways other than ARF-MDM-2-p53 are involved in order to overcome the proapoptotic effect of activated MYC. The inactivation of the p53 pathway occurs more often in permanent BL cell lines compared to primary tumor biopsies. 
Figure 2
The CDKN2A locus is not deleted in BL tumor samples. Example of an FISH analysis of the CDKN2A locus (red) and a chromosome 9 centromeric probe (green). Two adjacent red and green signals per nucleus indicate that the CDKN2A locus is not deleted.
Figure 3
Expression of ARF is not reduced in the BL samples but increased in 10. The expression level of ARF mRNA normalized to the expression of ABL mRNA in the 24 BL samples and in lymphocytes from 13 healthy blood donors quantitated by the formula 2
ÀWWCt . The line denotes mean þ 3 s.d. of the ARF expression level in the lymphocytes from the 13 blood donors.
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